Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer (Q37495410)

20 August 2017

Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer (English)

1 reference

20 August 2017

0 references

1 reference

hepatocellular carcinoma

1 reference

1 reference

Henry C Pitot

1 reference

20 August 2017

Charles Erlichman

1 reference

20 August 2017

Michelle R Mahoney

1 reference

20 August 2017

Kyle D Holen

1 reference

20 August 2017

Joel Picus

1 reference

20 August 2017

Donald W Northfelt

1 reference

20 August 2017

Philip A. Philip

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21953248

13 December 2024

Patrick J. Flynn

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21953248

13 December 2024

language of work or name

English

0 references

publication date

27 September 2011

1 reference

full work available at URL

20 August 2017

https://europepmc.org/articles/pmc3896238?pdf=render

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21953248

https://europepmc.org/articles/PMC3896238

13 December 2024

file format

HyperText Markup Language

online access status

open access

content deliverer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21953248

https://europepmc.org/articles/PMC3896238?pdf=render

13 December 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21953248

https://doi.org/10.1002/cncr.26556

13 December 2024

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21953248

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncr.26556

13 December 2024

1 reference

https://api.crossref.org/works/10.1002/CNCR.26556

https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.26556

13 December 2024

1 reference

https://api.crossref.org/works/10.1002/CNCR.26556

13 December 2024

1 reference

20 August 2017

118

1 reference

20 August 2017

1 reference

20 August 2017

2424-2430

1 reference

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896238

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896238

Sorafenib in advanced hepatocellular carcinoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896238

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896238

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896238

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896238

The epidermal growth factor receptor and its inhibition in cancer therapy

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896238

Systemic and regional treatment of primary carcinoma of the liver

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896238

Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896238

Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896238

Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896238

Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3896238

Treatment of hepatocellular carcinoma

2 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCNCR.26556

[Expression of vascular endothelial growth factor correlates with invasion and metastasis of hepatocellular carcinoma]

21 January 2018

1 reference

12 December 2020

One-sample multiple testing procedure for phase II clinical trials

1 reference

12 December 2020

[EGFR expression and EGF stimulation of proliferation in human liver carcinoma cells]

1 reference

12 December 2020

Immunohistochemical and ultrastructural localization of epidermal growth factor receptor in human liver and hepatocellular carcinoma tissues

1 reference

12 December 2020

Concomitant and isolated expression of TGF-alpha and EGF-R in human hepatoma cells supports the hypothesis of autocrine, paracrine, and endocrine growth of human hepatoma

1 reference

12 December 2020

Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor

1 reference

12 December 2020

Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma

1 reference

12 December 2020

Treatment of hepatocellular carcinoma

1 reference

12 December 2020

Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma

1 reference

12 December 2020

Rising incidence of hepatocellular carcinoma in the United States

1 reference

12 December 2020

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

12 December 2020

Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma

1 reference

12 December 2020

Expression of vascular endothelial growth factor in surgical specimens of hepatocellular carcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1002/CNCR.26556

1 reference

release_4fza7ogggzfa3gk5gutxq2pfci

20 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4fza7ogggzfa3gk5gutxq2pfci

24 November 2022

mapped directly with Wikidata item

1 reference

20 August 2017

1 reference